Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Bioorg Med Chem Lett. 2011 Oct 1;21(19):5711-4. doi: 10.1016/j.bmcl.2011.08.032. Epub 2011 Aug 11.

    Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.

    Source

    Pharmacology and Toxicology, RTI International, 3040 Cornwallis Rd., Research Triangle Park, NC 27709-2194, USA.

    Abstract

    CB1 receptor antagonists that are peripherally restricted were targeted. Compounds with permanent charge as well as compounds that have increased polar surface area were made and tested against CB1 for binding and activity. Sulfonamide and sulfamide with high polar surface area and good activity at CB1 were rationally designed and pharmacologically tested. Further optimization of these compounds and testing could lead to the development of a new class of therapeutics to treat disorders where the CB1 receptor system has been implicated.

    Copyright © 2011 Elsevier Ltd. All rights reserved.

    PMID:
    21875798
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3171605
    Free PMC Article

    Images from this publication.See all images (3)Free text

    Figure 1
    Scheme 1
    Scheme 2

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk